- 专利标题: Anti-CXCR4 antibodies and antibody-drug conjugates
-
申请号: US16535477申请日: 2019-08-08
-
公开(公告)号: US10927178B2公开(公告)日: 2021-02-23
- 发明人: Shu-Hui Liu , Flavia Mercer Pernasetti , Wei-Hsien Ho
- 申请人: PFIZER INC.
- 申请人地址: US NY New York
- 专利权人: PFIZER INC.
- 当前专利权人: PFIZER INC.
- 当前专利权人地址: US NY New York
- 代理机构: Pfizer Inc.
- 主分类号: C12N15/09
- IPC分类号: C12N15/09 ; C12N5/10 ; C07K16/28 ; C07K14/715 ; A61K39/395 ; C07H21/04 ; A61K49/00 ; A61K47/68 ; A61K39/00
摘要:
The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.